Regencell Bioscience Holdings Net Income
| RGC Stock | USD 27.23 2.16 8.62% |
As of the 7th of February, Regencell Bioscience holds the Risk Adjusted Performance of 0.0941, semi deviation of 8.63, and Coefficient Of Variation of 951.33. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regencell Bioscience, as well as the relationship between them.
Regencell Bioscience Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -3.2 M | -3.1 M | |
| Net Loss | -3.9 M | -4.1 M | |
| Net Loss | -6.7 M | -6.4 M | |
| Net Loss | (0.01) | (0.01) | |
| Net Income Per E B T | 0.89 | 0.78 |
Regencell | Net Income | Build AI portfolio with Regencell Stock |
Analyzing Regencell Bioscience's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Regencell Bioscience's current valuation and future prospects.
Latest Regencell Bioscience's Net Income Growth Pattern
Below is the plot of the Net Income of Regencell Bioscience Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Regencell Bioscience financial statement analysis. It represents the amount of money remaining after all of Regencell Bioscience Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Regencell Bioscience's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regencell Bioscience's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (3.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Regencell Net Income Regression Statistics
| Arithmetic Mean | 57,145,864 | |
| Coefficient Of Variation | 125.36 | |
| Mean Deviation | 66,021,053 | |
| Median | (390,990) | |
| Standard Deviation | 71,635,835 | |
| Sample Variance | 5131.7T | |
| Range | 177.8M | |
| R-Value | (0.75) | |
| Mean Square Error | 2381.2T | |
| R-Squared | 0.56 | |
| Significance | 0.0005 | |
| Slope | (10,662,916) | |
| Total Sum of Squares | 82107.1T |
Regencell Net Income History
Other Fundumenentals of Regencell Bioscience
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Regencell Bioscience Net Income component correlations
Regencell Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Regencell Bioscience is extremely important. It helps to project a fair market value of Regencell Stock properly, considering its historical fundamentals such as Net Income. Since Regencell Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regencell Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regencell Bioscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Regencell diversify its offerings? Factors like these will boost the valuation of Regencell Bioscience. Anticipated expansion of Regencell directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regencell Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Regencell Bioscience using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regencell Bioscience's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regencell Bioscience's market price to deviate significantly from intrinsic value.
It's important to distinguish between Regencell Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regencell Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regencell Bioscience's market price signifies the transaction level at which participants voluntarily complete trades.
Regencell Bioscience 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Regencell Bioscience's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Regencell Bioscience.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Regencell Bioscience on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Regencell Bioscience Holdings or generate 0.0% return on investment in Regencell Bioscience over 90 days. Regencell Bioscience is related to or competes with Cytokinetics, AptarGroup, Grifols SA, Abivax SA, Rhythm Pharmaceuticals, Stevanato Group, and Axsome Therapeutics. Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company More
Regencell Bioscience Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Regencell Bioscience's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Regencell Bioscience Holdings upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.47 | |||
| Information Ratio | 0.0983 | |||
| Maximum Drawdown | 86.33 | |||
| Value At Risk | (14.53) | |||
| Potential Upside | 22.98 |
Regencell Bioscience Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regencell Bioscience's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Regencell Bioscience's standard deviation. In reality, there are many statistical measures that can use Regencell Bioscience historical prices to predict the future Regencell Bioscience's volatility.| Risk Adjusted Performance | 0.0941 | |||
| Jensen Alpha | 1.36 | |||
| Total Risk Alpha | 0.0726 | |||
| Sortino Ratio | 0.1374 | |||
| Treynor Ratio | 5.22 |
Regencell Bioscience February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0941 | |||
| Market Risk Adjusted Performance | 5.23 | |||
| Mean Deviation | 8.54 | |||
| Semi Deviation | 8.63 | |||
| Downside Deviation | 9.47 | |||
| Coefficient Of Variation | 951.33 | |||
| Standard Deviation | 13.23 | |||
| Variance | 174.99 | |||
| Information Ratio | 0.0983 | |||
| Jensen Alpha | 1.36 | |||
| Total Risk Alpha | 0.0726 | |||
| Sortino Ratio | 0.1374 | |||
| Treynor Ratio | 5.22 | |||
| Maximum Drawdown | 86.33 | |||
| Value At Risk | (14.53) | |||
| Potential Upside | 22.98 | |||
| Downside Variance | 89.59 | |||
| Semi Variance | 74.49 | |||
| Expected Short fall | (10.41) | |||
| Skewness | 1.74 | |||
| Kurtosis | 6.15 |
Regencell Bioscience Backtested Returns
Regencell Bioscience is slightly risky given 3 months investment horizon. Regencell Bioscience maintains Sharpe Ratio (i.e., Efficiency) of 0.13, which implies the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to analyze and collect data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.77% are justified by taking the suggested risk. Use Regencell Bioscience Coefficient Of Variation of 951.33, risk adjusted performance of 0.0941, and Semi Deviation of 8.63 to evaluate company specific risk that cannot be diversified away. Regencell Bioscience holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 0.26, which implies not very significant fluctuations relative to the market. As returns on the market increase, Regencell Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Regencell Bioscience is expected to be smaller as well. Use Regencell Bioscience jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to analyze future returns on Regencell Bioscience.
Auto-correlation | -0.31 |
Poor reverse predictability
Regencell Bioscience Holdings has poor reverse predictability. Overlapping area represents the amount of predictability between Regencell Bioscience time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Regencell Bioscience price movement. The serial correlation of -0.31 indicates that nearly 31.0% of current Regencell Bioscience price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.31 | |
| Spearman Rank Test | -0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 57.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Regencell Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Regencell Bioscience Holdings reported net income of (3.58 Million). This is 101.05% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.63% higher than that of the company.
Regencell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regencell Bioscience's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regencell Bioscience could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics of similar companies.Regencell Bioscience is currently under evaluation in net income category among its peers.
Regencell Bioscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regencell Bioscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regencell Bioscience's managers, analysts, and investors.Environmental | Governance | Social |
Regencell Bioscience Institutional Holders
Institutional Holdings refers to the ownership stake in Regencell Bioscience that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Regencell Bioscience's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Regencell Bioscience's value.| Shares | Citigroup Inc | 2025-06-30 | 70.0 | Royal Bank Of Canada | 2025-06-30 | 0.0 | Tower Research Capital Llc | 2025-06-30 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 391.1 K | Squarepoint Ops Llc | 2025-06-30 | 99.8 K | Schonfeld Strategic Advisors Llc | 2025-06-30 | 52.1 K | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 45 K | Ubs Group Ag | 2025-06-30 | 37.5 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 33 K | Y-intercept (hong Kong) Ltd | 2025-06-30 | 13 K | Greenfield Savings Bank | 2025-06-30 | 11 K |
Regencell Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 13.98 B | ||||
| Shares Outstanding | 494.49 M | ||||
| Shares Owned By Insiders | 88.55 % | ||||
| Shares Owned By Institutions | 0.13 % | ||||
| Number Of Shares Shorted | 924.71 K | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 2,877 X | ||||
| EBITDA | (3.19 M) | ||||
| Net Income | (3.58 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 544.41 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 13.94 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (3.11 M) | ||||
| Short Ratio | 1.11 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Price To Earnings To Growth | 2.15 X | ||||
| Number Of Employees | 10 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 12.4 B | ||||
| Total Asset | 5.76 M | ||||
| Retained Earnings | (25.2 M) | ||||
| Working Capital | 7.92 M | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
| Five Year Return | 4.37 % | ||||
| Net Asset | 5.76 M |
About Regencell Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regencell Bioscience Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regencell Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regencell Bioscience Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could Regencell diversify its offerings? Factors like these will boost the valuation of Regencell Bioscience. Anticipated expansion of Regencell directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regencell Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Regencell Bioscience using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regencell Bioscience's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regencell Bioscience's market price to deviate significantly from intrinsic value.
It's important to distinguish between Regencell Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regencell Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regencell Bioscience's market price signifies the transaction level at which participants voluntarily complete trades.